GlycoMimetics, Inc. (GLYC) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and thank you for joining the GlycoMimetics fourth quarter and full year 2022 earnings call. At this time, all participants are listed on the mode. Following the management's remarks, we will hold a question and answer session. At that time, lines will be open for you. I would now like to turn the call over to Christian Deneen Long, Company Counsel at GlycoMimetics. Please go ahead. Good morning. Today we will review our business updates and financial results for the quarter and full year ended December 31, 2022. The press release we issued this morning is available on the company's website at glycomimetics.com. This call is being recorded. A dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available for 30 days in the Investors section of the company's website. Joining me on the call today from GlycoMimetics are Harit Samarjan, Chief Executive Officer, Brian Hahn, Chief Financial Officer, and Dr. Edwin Rock, Chief Medical Officer. Today's call will include forward-looking statements based on our current expectations. Forward-looking statements may include, but are not limited to, statements about the company's product candidate, upralesolin, or our other pipeline programs, along with statements of our expectations regarding our operations, the conduct of or data from clinical trials, planned or potential development activities, regulatory interactions or submissions, pre-commercialization activities, potential strategic collaborations, and our cash position. Such statements represent management's judgment and intention as of today and involve assumptions, risks, and uncertainties. Glycomimetics undertakes no obligation to update or revise any forward-looking statement. For information conc...